Abstract
We applied antisense RNA technology for reducing the level of human IFN-gamma (HuIFN-gamma) expression. An antisense RNA vector containing the full-length HuIFN-gamma cDNA in the opposite orientation was electroporated into cells constitutively producing very high levels of the cytokine. Approximately 53% of the resulting clones exhibited a specific HuIFN-gamma inhibition of an average of 95.5%. The results of reverse transcription-polymerase chain reaction and Northern blot analyses revealed that the antisense effect originated from a specific reduction of the targeted mRNA caused by antisense RNA expression. This very effective antisense RNA strategy can have possible therapeutic applications in treating diseases where HuIFN-gamma is known to play a negative role, such as in certain autoimmune diseases.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|